ArticleClinical case reports2026
Steroid-Free Remission of Eosinophilic Granulomatosis With Polyangiitis Achieved With Low-Dose Mepolizumab: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 73-year-old man with a history of severe asthma was admitted to our hospital with progressive dyspnea, weight loss, polyarthralgia, and myalgia. Laboratory tests revealed peripheral eosinophilia and anti-myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) negativity. Chest computed tomography revealed diffuse ground-glass opacities, interlobular septal, and bronchial wall thickening, suggesting eosinophilic pulmonary infiltration. Based on this clinical presentation and the ACR/EULAR 2022 classification criteria, as well as the Japanese Ministry of Health, Labour and Welfare criteria, eosinophilic granulomatosis with polyangiitis (EGPA) was diagnosed. However, the patient declined treatment with glucocorticoids owing to concurrent diabetes mellitus; therefore, subcutaneous low-dose (100 mg/month) mepolizumab monotherapy was initiated as an alternative strategy, with the lower dose specifically selected to alleviate the patient's financial burden. Notably, a rapid decrease in eosinophil counts was observed within just 4 days of administration, and remission was achieved and maintained for 2 years. In conclusion, this case suggests that mepolizumab monotherapy may be a viable option for certain patients with non-severe, MPO-ANCA-negative EGPA who cannot tolerate standard high-dose glucocorticoid therapy or have financial constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.